18.10.01 · organismal-bio / immunology

Immunology

shipped3 tiersLean: nonepending prereqs

Anchor (Master): Janeway's Immunobiology, 10th ed. (2022); Murphy & Weaver — Janeway; relevant primary literature

Intuition Beginner

Your immune system is your body's defense force. It has two divisions that work together: the innate immune system (fast, general, born ready) and the adaptive immune system (slow to start, highly specific, remembers past encounters).

The innate immune system is the first responder. It includes physical barriers (skin, mucous membranes), chemical barriers (stomach acid, lysozyme in tears), phagocytes (cells that engulf and destroy pathogens -- macrophages and neutrophils), natural killer (NK) cells (that kill virus-infected and cancerous cells), the complement system (a cascade of blood proteins that punch holes in bacterial membranes), and inflammation (the redness, heat, swelling, and pain that accompany infection, caused by increased blood flow and immune cell infiltration).

The innate system recognizes general patterns common to many pathogens (bacterial cell wall components, viral double-stranded RNA) using pattern recognition receptors (PRRs) such as Toll-like receptors (TLRs). This recognition is fast (minutes to hours) but not highly specific -- the innate system cannot distinguish between different strains of the same bacterium.

The adaptive immune system is slower (days to respond) but far more precise. It has two main branches: the humoral response (B cells producing antibodies) and the cell-mediated response (T cells killing infected cells). The key feature of adaptive immunity is specificity -- each B or T cell recognizes exactly one specific molecular shape (an antigen) through unique receptors. The human immune system can generate approximately 10^11 different antibody specificities, enough to recognize virtually any pathogen.

When a B or T cell encounters its specific antigen, it proliferates rapidly (clonal selection), producing many daughter cells that all recognize the same antigen. Some of these become effector cells (that fight the current infection) and some become memory cells (that persist for years or decades, enabling a faster and stronger response if the same pathogen returns). This is the basis of vaccination: exposing the immune system to a harmless version of a pathogen generates memory cells that protect against future infection.

Visual Beginner

Feature	Innate immunity	Adaptive immunity
Response time	Minutes to hours	Days
Specificity	Broad (pattern-based)	Highly specific (antigen-based)
Memory	No	Yes (memory B and T cells)
Key cells	Macrophages, neutrophils, NK cells	B cells, T cells
Key molecules	Complement, cytokines, defensins	Antibodies, T cell receptors
Diversity	Limited (germline-encoded receptors)	Vast (gene rearrangement generates ~10^11 specificities)

The adaptive immune response:

Pathogen enters body
        |
   Innate immunity responds first (phagocytes, inflammation)
        |
   Antigen-presenting cells (dendritic cells) capture antigen
        |
   Dendritic cells migrate to lymph nodes and present antigen to T cells
       / \
      /   \
  B cells   T cells
     |         |
  Antibodies   Cytotoxic T cells (kill infected cells)
     |         |
  Neutralize   Helper T cells (coordinate the response)
  pathogens    |
     |         |
  Together: clear the infection and form memory cells

Worked example Beginner

Consider how the immune system responds to a cut on your finger that introduces the bacterium Staphylococcus aureus.

Step 1. Barrier breach. The skin is broken, allowing bacteria to enter the tissue. Platelets clot the wound to limit blood loss but also create a scaffold for bacterial growth.

Step 2. Innate response (0-4 hours). Tissue macrophages (already present) recognize bacterial components via TLRs and begin phagocytosing bacteria. They release cytokines (IL-1, TNF-alpha, IL-6) that cause local blood vessels to dilate and become more permeable -- this is inflammation (redness, heat, swelling). Complement proteins in the blood are activated by bacterial surfaces, forming membrane attack complexes (MACs) that lyse bacteria directly.

Step 3. Neutrophil recruitment (4-24 hours). Cytokines and chemokines attract neutrophils from the blood to the infection site. Neutrophils are short-lived phagocytes that arrive in large numbers, engulf bacteria, and release toxic granules containing reactive oxygen species and proteases. Pus is largely dead neutrophils and bacteria.

Step 4. Adaptive response initiation (24-72 hours). Dendritic cells in the tissue phagocytose bacteria, process bacterial proteins into peptide fragments, and display these fragments on MHC molecules on their surface. The dendritic cells migrate to the nearest lymph node, where they present these peptide-MHC complexes to T cells. If a T cell's receptor matches the peptide, the T cell becomes activated, proliferates (clonal expansion), and differentiates into effector and memory T cells.

Step 5. Humoral response (days 5-7). Helper T cells activate B cells that have bound the same bacterial antigen. Activated B cells proliferate and differentiate into plasma cells (antibody factories) and memory B cells. Antibodies specific to S. aureus enter the bloodstream and reach the infection site, where they opsonize bacteria (mark them for phagocytosis), neutralize bacterial toxins, and activate complement more efficiently.

Step 6. Resolution. Once the infection is cleared, most effector cells die by apoptosis. Memory B and T cells persist, providing rapid protection if S. aureus enters again.

Check your understanding Beginner

Exercise (easy, multiple choice).

What is the primary role of memory B and T cells?

A. To fight the current infection B. To produce complement proteins C. To provide a faster, stronger immune response upon re-exposure to the same pathogen D. To present antigens to other immune cells

Hint

Memory cells are generated during the first exposure to an antigen but do not actively fight the current infection. Their value becomes apparent on the second exposure.

Answer

Option C. Memory B and T cells are long-lived cells generated during the primary immune response. They express the same antigen-specific receptor as the original effector cells but remain in a quiescent state. Upon re-exposure to the same pathogen, memory cells are activated much more quickly and in greater numbers than naive cells, producing a secondary immune response that is faster (hours instead of days), stronger (higher antibody titers), and higher affinity (due to somatic hypermutation). This is why vaccines work: they generate memory cells without causing disease.

Exercise (easy, true/false).

The innate immune system can distinguish between different strains of the same bacterial species.

Hint

The innate immune system recognizes general patterns (PAMPs -- pathogen-associated molecular patterns), not specific molecular sequences. How specific are pattern recognition receptors?

Answer

False. The innate immune system recognizes broad molecular patterns shared by classes of pathogens (e.g., lipopolysaccharide in Gram-negative bacteria, peptidoglycan in Gram-positive bacteria, double-stranded RNA in viruses). These pattern recognition receptors cannot distinguish between different strains of the same species. It is the adaptive immune system, with its vast repertoire of antigen-specific receptors generated by gene rearrangement, that can make fine distinctions between closely related pathogens.

Formal definition Intermediate+

The immune system is the set of cells, tissues, and molecules that defend the body against pathogens and transformed cells. It is organized into innate and adaptive arms that cooperate through cell-cell contact, cytokine signaling, and complement activation.

Innate immunity

Physical and chemical barriers: Skin (keratinized stratified squamous epithelium, acidic pH ~5), mucous membranes (mucus traps pathogens, mucociliary clearance), gastric acid (pH ~2 kills most ingested organisms), lysozyme (degrades bacterial peptidoglycan), defensins (antimicrobial peptides that disrupt microbial membranes).

Phagocytes: Macrophages (tissue-resident, long-lived, derived from monocytes) and neutrophils (short-lived, blood-borne, recruited to sites of infection by chemokines) engulf pathogens into phagosomes, which fuse with lysosomes to form phagolysosomes where the pathogen is destroyed by reactive oxygen species (the respiratory burst, catalyzed by NADPH oxidase), nitric oxide, and hydrolytic enzymes.

NK cells recognize cells that have downregulated MHC class I (a common viral evasion strategy) or that express stress-induced ligands. NK cell killing is regulated by a balance of activating and inhibitory receptors: inhibitory receptors (KIRs, CD94/NKG2A) engage MHC class I and suppress killing; loss of MHC class I removes inhibitory signaling ("missing-self" recognition), permitting NK cell degranulation.

Complement: Three activation pathways -- classical (antibody-dependent), lectin (mannose-binding lectin), and alternative (spontaneous hydrolysis of C3) -- converge on C3 convertase, which cleaves C3 into C3a (anaphylatoxin, promotes inflammation) and C3b (opsonin, coats pathogen surface). The terminal pathway forms the membrane attack complex (MAC: C5b-9), a pore that lyses the pathogen.

Inflammation is the coordinated response to tissue damage and infection, characterized by rubor (redness), tumor (swelling), calor (heat), and dolor (pain). Mediated by histamine (from mast cells), prostaglandins, bradykinin, and cytokines (IL-1, TNF-alpha, IL-6). Acute inflammation resolves within days; chronic inflammation (persistent stimulus) can cause tissue damage and is implicated in autoimmune diseases, atherosclerosis, and cancer.

Adaptive immunity

B cells and antibodies. Each B cell expresses a unique membrane-bound antibody (B cell receptor, BCR) generated by V(D)J recombination of immunoglobulin gene segments. The human immunoglobulin heavy chain locus contains approximately 40 V (variable), 23 D (diversity), and 6 J (joining) segments; random recombination of one each produces approximately $40 \times 23 \times 6 = 5, 520$ combinations. Combined with light chain recombination (V-J for kappa and lambda chains) and junctional diversity (random addition and deletion of nucleotides at segment junctions by TdT), the total repertoire exceeds $1 0^{11}$ specificities.

Antibody classes (isotypes): IgM (first responder, pentameric), IgG (most abundant in serum, crosses placenta), IgA (mucosal immunity, dimeric with secretory component), IgE (allergy, parasitic defense, bound to mast cells and basophils), IgD (function less clear, found on naive B cells).

T cells. T cells recognize peptide antigens presented by MHC molecules on the surface of other cells. CD8+ cytotoxic T cells (CTLs) recognize peptides presented on MHC class I (found on all nucleated cells) and kill virus-infected or cancerous cells by releasing perforin (forms pores in the target membrane) and granzymes (serine proteases that activate caspases, triggering apoptosis). CD4+ helper T cells recognize peptides on MHC class II (found on professional antigen-presenting cells: dendritic cells, macrophages, B cells) and coordinate the immune response through cytokine secretion.

Antigen presentation. MHC class I presents endogenous (intracellular) peptides -- viral peptides, tumor antigens -- to CD8+ T cells. MHC class II presents exogenous (extracellular) peptides -- bacterial peptides from phagocytosed organisms -- to CD4+ T cells. The MHC is highly polymorphic: the human population carries thousands of HLA (human leukocyte antigen) alleles, ensuring that at least some individuals in a population can present any given pathogen peptide.

Clonal selection. When a naive lymphocyte encounters its specific antigen (presented by an antigen-presenting cell for T cells, or directly bound by the BCR for B cells), it undergoes clonal expansion: proliferation producing thousands of identical daughter cells. These differentiate into effector cells (plasma cells, CTLs, helper T cells) and memory cells. This process takes 4-7 days, which is why adaptive responses are slower than innate responses.

Key results Intermediate+

Result 1 (Clonal selection theory). Burnet's clonal selection theory (1957) states that each lymphocyte expresses receptors specific for one antigen before ever encountering that antigen. Upon antigen binding, the lymphocyte is selected (activated) and proliferates, generating a clone of cells with identical specificity. This theory predicts that removing a specific clone (clonal deletion) eliminates the response to that antigen, and that tolerance to self-antigens results from the deletion or inactivation of self-reactive clones during lymphocyte development.

Result 2 (MHC restriction). Zinkernagel and Doherty (1974, Nobel Prize 1996) demonstrated that cytotoxic T cells recognize antigen only when presented by the same MHC molecule that was present during the T cell's development. T cells are "restricted" to recognizing their specific peptide only in the context of a specific MHC allele. This explains why tissue transplants between individuals with different MHC types are rejected: T cells see the foreign MHC as non-self.

Exercise 1

Exercise 1 (medium, short answer).

Explain how V(D)J recombination generates antibody diversity, naming the enzymatic machinery involved and estimating the total diversity generated.

Hint

Three sources of diversity: combinatorial (which segments are chosen), junctional (random addition/deletion at junctions), and pairing (heavy + light chain combinations). The enzymes RAG1/RAG2 initiate recombination; TdT adds random nucleotides.

Answer

V(D)J recombination generates antibody diversity through three mechanisms:

Combinatorial diversity. Random selection of V, D, and J segments from the available pools. For the human heavy chain: ~40 V x 23 D x 6 J = ~5,520 combinations. For the kappa light chain: ~40 V x 5 J = ~200 combinations. For the lambda light chain: ~30 V x 4 J = ~120 combinations.
Junctional diversity. The enzyme terminal deoxynucleotidyl transferase (TdT) adds random (non-templated) nucleotides at the V-D and D-J junctions of the heavy chain, and at the V-J junction of the light chain. Additionally, an exonuclease randomly removes nucleotides from the segment ends. This creates enormous diversity at the third complementarity-determining region (CDR3), which is the most variable part of the antibody and the primary determinant of antigen specificity. Junctional diversity contributes approximately $1 0^{7}$ - to $1 0^{8}$ -fold variation.
Heavy-light chain pairing. Each heavy chain can pair with any light chain (kappa or lambda), multiplying the diversity. With approximately 5,520 heavy chain combinations and approximately 320 light chain combinations: $5, 520 \times 320 \approx 1.8 \times 1 0^{6}$ combinations from combinatorial diversity alone.

The enzymes RAG1 and RAG2 (recombination-activating genes) initiate V(D)J recombination by making double-strand breaks at recombination signal sequences flanking each gene segment. The DNA-PKcs/Ku70/Ku80 complex, Artemis nuclease, and DNA ligase IV/XRCC4 complex resolve the breaks.

Total diversity, combining all mechanisms: approximately $1 0^{11}$ unique antibody specificities.

Exercise 2

Exercise 2 (medium, short answer).

Compare and contrast autoimmune diseases, allergies, and immunodeficiency. For each, describe what goes wrong with the immune system and give one specific example.

Hint

Autoimmune: immune system attacks self. Allergy: immune system overreacts to harmless substance. Immunodeficiency: immune system is too weak.

Answer

Autoimmune diseases: The immune system fails to maintain self-tolerance and attacks the body's own tissues. Normally, self-reactive lymphocytes are eliminated (central tolerance in the bone marrow and thymus) or inactivated (peripheral tolerance by regulatory T cells and anergy). In autoimmunity, these mechanisms fail. Example: Type 1 diabetes -- autoreactive T cells destroy insulin-producing beta cells in the pancreatic islets, causing insulin deficiency.

Allergies (hypersensitivity): The immune system mounts an inappropriate response against a harmless environmental antigen (allergen). Type I hypersensitivity (immediate) involves IgE production against the allergen, IgE binding to mast cells and basophils, and subsequent allergen exposure triggering mast cell degranulation (release of histamine, leukotrienes, prostaglandins). Example: Peanut allergy -- IgE against peanut proteins causes anaphylaxis upon exposure, with systemic histamine release causing airway constriction, hypotension, and potentially death.

Immunodeficiency: The immune system is unable to mount an effective response against pathogens. Primary immunodeficiencies are genetic (e.g., SCID -- severe combined immunodeficiency, caused by mutations in genes required for lymphocyte development, including ADA deficiency or RAG1/RAG2 mutations). Secondary immunodeficiencies are acquired (e.g., HIV/AIDS -- HIV infects and depletes CD4+ T cells, crippling both humoral and cell-mediated immunity and leading to opportunistic infections).

Advanced treatment Master

The molecular mechanisms of adaptive immunity involve somatic DNA recombination, receptor signaling cascades, and a sophisticated system of tolerance that prevents self-reactivity while maintaining the capacity to respond to virtually any foreign antigen.

V(D)J recombination is the only known site-specific DNA rearrangement in vertebrates. RAG1 and RAG2 form a complex that recognizes recombination signal sequences (RSS) flanking V, D, and J gene segments. Each RSS consists of a conserved heptamer (CACAGTG) and nonamer (ACAAAAACC) separated by either 12 or 23 bp spacers. The 12/23 rule ensures correct segment pairing: a 12-spacer RSS can only recombine with a 23-spacer RSS. RAG introduces a nick at the heptamer-coding segment boundary, then catalyzes a transesterification reaction that forms a hairpin at the coding end and a blunt signal end. Artemis nuclease opens the hairpin (generating palindromic P nucleotides if the opening is asymmetric), TdT adds N nucleotides, and the nonhomologous end joining (NHEJ) pathway ligates the coding joint.

Somatic hypermutation (SHM) and affinity maturation. After antigen activation, B cells in germinal centers of lymph nodes undergo SHM: activation-induced cytidine deaminase (AID) deaminates cytidine to uridine in the variable regions of immunoglobulin genes, creating U mismatches. Error-prone repair by uracil-DNA glycosylase (UNG) and mismatch repair (MSH2/6) introduces point mutations at a rate approximately $1 0^{6}$ -fold higher than the basal somatic mutation rate. B cells bearing higher-affinity BCRs (resulting from favorable mutations) receive survival signals from follicular helper T cells (Tfh); those with lower-affinity or autoreactive BCRs undergo apoptosis. This affinity maturation process progressively improves antibody quality over the course of an immune response.

Isotype switching (class switch recombination). AID also mediates class switch recombination, which changes the antibody isotype from IgM to IgG, IgA, or IgE while preserving antigen specificity. AID initiates double-strand breaks in switch regions (repetitive DNA sequences) upstream of each constant region gene. The intervening DNA is excised, and the V(D)J region is joined to a downstream constant region. The cytokine milieu determines which isotype is switched to: IL-4 promotes switching to IgE and IgG1; TGF-beta promotes switching to IgA; IFN-gamma promotes switching to IgG2a.

T cell development and selection. T cell precursors migrate from the bone marrow to the thymus, where they undergo a rigorous selection process. Positive selection in the thymic cortex: thymocytes whose TCRs can weakly recognize self-MHC molecules (with self-peptides) receive survival signals; those that cannot bind any self-MHC die by neglect (approximately 90% of thymocytes). Negative selection in the thymic medulla: thymocytes whose TCRs bind strongly to self-peptide-MHC complexes are deleted by apoptosis, preventing autoimmunity. The medullary thymic epithelial cells (mTECs) express the transcription factor AIRE (autoimmune regulator), which promiscuously expresses tissue-specific antigens (insulin, thyroglobulin, myelin basic protein) in the thymus, enabling negative selection against self-reactive T cells specific for antigens normally restricted to peripheral tissues. AIRE mutations cause APECED (autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy), demonstrating the critical role of central tolerance.

Regulatory T cells (Tregs) are a subset of CD4+ T cells that maintain peripheral tolerance. Natural Tregs (nTregs) develop in the thymus; induced Tregs (iTregs) differentiate from naive CD4+ T cells in the periphery under tolerogenic conditions. Both express the transcription factor FoxP3 (mutations in which cause IPEX syndrome -- immune dysregulation, polyendocrinopathy, enteropathy, X-linked). Tregs suppress immune responses through multiple mechanisms: secretion of inhibitory cytokines (IL-10, TGF-beta), cytolysis of effector T cells, metabolic disruption (CD25-mediated IL-2 consumption), and modulation of dendritic cell function (CTLA-4 binding to CD80/86 on dendritic cells). Cancer immunology has identified tumor-infiltrating Tregs as a major mechanism of immune evasion: tumors recruit and activate Tregs that suppress anti-tumor T cell responses. Immune checkpoint inhibitors (anti-CTLA-4, anti-PD-1) partly work by disrupting Treg-mediated suppression.

The inflammasome is a multiprotein complex that activates caspase-1, which processes pro-IL-1beta and pro-IL-18 into their active forms and triggers pyroptosis (inflammatory cell death). NLRP3, the best-characterized inflammasome, is activated by diverse stimuli: ATP (via P2X7 receptor and K+ efflux), crystalline substances (uric acid crystals in gout, asbestos, silica), reactive oxygen species, and lysosomal damage. Gain-of-function mutations in NLRP3 cause cryopyrin-associated periodic syndromes (CAPS), a group of autoinflammatory diseases. Inhibiting IL-1beta (with the recombinant IL-1 receptor antagonist anakinra or the monoclonal antibody canakinumab) treats these conditions.

Comparative immunology across vertebrates. The adaptive immune system (B cells, T cells, antibodies, MHC molecules) is a jawed vertebrate innovation, appearing approximately 500 million years ago. Jawless vertebrates (lampreys and hagfish) have independently evolved an alternative adaptive immune system based on variable lymphocyte receptors (VLRs) that use leucine-rich repeats rather than immunoglobulin domains for antigen recognition, generating diversity through a gene conversion mechanism rather than V(D)J recombination. This convergent evolution of adaptive immunity in two vertebrate lineages demonstrates the strong selective advantage of somatic immune diversification.

Invertebrates rely entirely on innate immunity, but their innate systems are far more sophisticated than once believed. Insects have both cellular immunity (hemocytes that phagocytose and encapsulate pathogens) and humoral immunity (antimicrobial peptides induced by the Toll and Imd pathways, which are ancestral to the vertebrate Toll-like receptor and TNF signaling pathways, respectively). The fruit fly Toll pathway, discovered by Jules Hoffmann and colleagues (Nobel Prize 2011), provided the first demonstration that innate immunity involves specific pathogen recognition through germline-encoded receptors -- a principle later extended to vertebrate TLRs by Bruce Beutler.

T cell exhaustion and immune checkpoint therapy. During chronic viral infections and cancer, T cells enter a state of functional exhaustion characterized by progressive loss of effector functions (cytokine production, cytotoxic activity, proliferative capacity) and sustained expression of inhibitory receptors (PD-1, CTLA-4, TIM-3, LAG-3). T cell exhaustion was first characterized in chronic LCMV infection in mice by Rafi Ahmed and colleagues. The exhausted state is not simply T cell inactivation but a distinct transcriptional program regulated by the transcription factors TOX and NR4A, which rewire gene expression from effector to exhausted programming.

The discovery of immune checkpoint molecules and their role in T cell exhaustion has transformed cancer therapy. James Allison demonstrated that blocking CTLA-4 (which competes with CD28 for binding to B7 molecules on antigen-presenting cells, delivering an inhibitory signal) could unleash anti-tumor T cell responses in mice. Tasuku Honjo discovered PD-1 and showed that PD-1 blockade similarly enhanced anti-tumor immunity. Both received the Nobel Prize in 2018. Immune checkpoint inhibitors (anti-CTLA-4: ipilimumab; anti-PD-1: nivolumab, pembrolizumab) have produced durable responses in a subset of patients with metastatic melanoma, lung cancer, and other malignancies, representing one of the most significant advances in cancer treatment. However, checkpoint inhibition can also trigger autoimmune side effects (colitis, pneumonitis, endocrinopathies) by removing the brakes on self-reactive T cells, illustrating the fundamental trade-off between immune activation and self-tolerance.

Vaccines: mechanisms and the immune basis of protection. Vaccines work by generating immunological memory without causing disease. Different vaccine platforms exploit different aspects of the immune response. Live attenuated vaccines (MMR, varicella) replicate within the host, generating robust humoral and cellular immunity through prolonged antigen exposure that mimics natural infection. Inactivated vaccines (influenza, hepatitis A) contain killed pathogens that cannot replicate but present surface antigens to the immune system; they typically require adjuvants (aluminum salts, oil-in-water emulsions) to enhance the immune response and booster doses to maintain immunity. Subunit vaccines (hepatitis B, HPV) contain purified protein antigens (recombinant surface proteins or virus-like particles) that focus the immune response on key neutralizing epitopes. mRNA vaccines (COVID-19: BNT162b2, mRNA-1273) deliver nucleoside-modified mRNA encoding a viral antigen (the SARS-CoV-2 spike protein) in lipid nanoparticles; host cells translate the mRNA into protein, which is then presented on MHC class I (activating CD8+ T cells) and secreted for uptake by antigen-presenting cells (activating CD4+ T cells and B cells). This dual activation produces both cellular and humoral immunity.

The immune correlates of protection vary by pathogen. For many viral infections, neutralizing antibody titers against surface proteins are the primary correlate: sufficiently high antibody levels prevent viral entry into host cells. For intracellular pathogens (tuberculosis) and cancer, cellular immunity (CD8+ T cell responses) is more important. The duration of immune memory also varies: a single dose of live attenuated measles vaccine provides lifelong protection, while influenza vaccines must be administered annually because influenza undergoes antigenic drift (accumulating mutations in surface proteins that allow escape from existing antibodies) and antigenic shift (reassortment of gene segments between strains, producing novel subtypes to which the population has no prior immunity).

Exercise 3

Exercise 3 (medium, short answer).

Compare the adaptive immune systems of jawed vertebrates and jawless vertebrates (lampreys). How do they achieve similar functional outcomes (immune diversity and memory) through different molecular mechanisms?

Hint

Jawed vertebrates use V(D)J recombination with immunoglobulin domains. Jawless vertebrates use leucine-rich repeat-based receptors. Both generate diversity through somatic recombination.

Answer

Jawed vertebrates (gnathostomes) and jawless vertebrates (cyclostomes: lampreys and hagfish) have independently evolved adaptive immune systems that achieve the same functional outcomes -- somatic diversification of antigen receptors and immunological memory -- through entirely different molecular mechanisms:

Jawed vertebrates: B cells and T cells generate diverse antigen receptors through V(D)J recombination of immunoglobulin (Ig) or T cell receptor (TCR) gene segments. The receptors are based on the immunoglobulin fold domain, and diversity is generated by RAG1/RAG2-mediated DNA recombination, TdT-mediated junctional diversity, and (for B cells) somatic hypermutation. Memory B cells and T cells provide long-lasting immunity.

Jawless vertebrates: Lampreys and hagfish have variable lymphocyte receptors (VLRs) that use leucine-rich repeat (LRR) modules rather than immunoglobulin domains as their antigen-binding units. Diversity is generated by a gene conversion mechanism in which a single germline VLR gene is assembled by randomly inserting LRR modules from a large flanking library of LRR cassettes. This somatic assembly produces an estimated diversity of over 10^14 unique VLRs. Two types of VLR-based lymphocytes (VLRA+ and VLRB+) appear to be functionally analogous to T cells and B cells, respectively. VLRB+ cells secrete soluble VLR antibodies; VLRA+ cells appear to function in cell-mediated immunity.

The convergent evolution of adaptive immunity in these two lineages demonstrates that somatic diversification of immune receptors is so advantageous that it has evolved twice, using completely different molecular architectures. This convergence suggests that the functional requirements of adaptive immunity (diversity, specificity, and memory) strongly constrain the possible solutions, and that somatic DNA rearrangement is a uniquely effective way to achieve the necessary receptor diversity.

Exercise 4

Exercise 4 (medium, short answer).

Explain how immune checkpoint inhibitors (anti-PD-1, anti-CTLA-4) work to enhance anti-tumor immunity. Why do these therapies sometimes cause autoimmune side effects?

Hint

PD-1 and CTLA-4 are inhibitory receptors on T cells that dampen immune responses. Tumors exploit these pathways to evade immune attack. Blocking them releases the brakes but also removes self-tolerance.

Answer

CTLA-4 and PD-1 are immune checkpoint molecules that function as brakes on T cell activation:

CTLA-4 is expressed on T cells after activation and competes with the costimulatory receptor CD28 for binding to B7 molecules (CD80/CD86) on antigen-presenting cells. CTLA-4 has higher affinity for B7 than CD28, so when CTLA-4 is present, it outcompetes CD28 and delivers an inhibitory signal that reduces T cell proliferation and IL-2 production. Anti-CTLA-4 antibodies (ipilimumab) block this interaction, allowing CD28 to engage B7 unimpeded, enhancing T cell activation and proliferation.

PD-1 is expressed on exhausted T cells in chronic infections and tumors. Its ligand PD-L1 is expressed on many tumor cells and on cells in the tumor microenvironment. When PD-1 engages PD-L1, it delivers an inhibitory signal that suppresses T cell effector functions (cytotoxicity, cytokine production). Tumors exploit this pathway by expressing PD-L1, effectively turning off infiltrating T cells. Anti-PD-1 antibodies (nivolumab, pembrolizumab) or anti-PD-L1 antibodies (atezolizumab) block this interaction, restoring T cell function.

Autoimmune side effects (immune-related adverse events) occur because checkpoint molecules also maintain peripheral self-tolerance. CTLA-4 is constitutively expressed on regulatory T cells (Tregs), where it enhances their suppressive function. PD-1/PD-L1 interactions in peripheral tissues prevent T cells from attacking healthy organs. When these checkpoints are blocked, self-reactive T cells that would normally be held in check can become activated, causing inflammation in the colon (colitis), lungs (pneumonitis), thyroid (thyroiditis), skin (rash, vitiligo), liver (hepatitis), and other organs. The frequency of autoimmune side effects reflects the fundamental trade-off between immune activation and self-tolerance: enhancing anti-tumor immunity inevitably risks breaking tolerance to self.

Exercise 5

Exercise 5 (hard, analysis).

The cheetah (Acinonyx jubatus) has remarkably low MHC diversity compared to other felids, likely due to a population bottleneck at the end of the last ice age. Explain how reduced MHC diversity affects immunological fitness and discuss the implications for conservation of endangered species with small population sizes.

Hint

MHC diversity determines the range of pathogen peptides that can be presented to T cells. Low MHC diversity means the population is susceptible to epidemics. How does this connect to genetic drift and the 50/500 rule?

Answer

MHC molecules present pathogen-derived peptides to T cells, and the extreme polymorphism of MHC genes in most vertebrate populations ensures that different individuals can present different pathogen peptides, providing population-level immune diversity. Reduced MHC diversity has several immunological consequences:

Narrower antigen presentation repertoire. With fewer MHC alleles, the population can present a smaller range of pathogen peptides to T cells. Pathogens that express peptides not efficiently bound by the limited MHC repertoire can infect most individuals in the population, creating vulnerability to epidemics.
Reduced capacity to respond to evolving pathogens. Pathogens evolve to evade immune recognition by mutating the peptide epitopes presented by the most common MHC alleles. In a diverse MHC population, some individuals will have rare alleles that the pathogen has not evolved to evade. In a monomorphic MHC population, all individuals share the same vulnerability.
Evidence from cheetahs. Cheetahs show MHC class I diversity approximately 10-15% of that seen in domestic cats. Skin grafts between unrelated cheetahs are accepted without immunosuppression, demonstrating histocompatibility similarity. In 1983, a feline infectious peritonitis (FIP) outbreak in a captive cheetah colony caused high mortality, consistent with the prediction that a novel pathogen can sweep through a genetically uniform population.

The conservation implications are significant. Many endangered species have undergone population bottlenecks that reduce MHC diversity through genetic drift. The 50/500 rule (an effective population size of 50 to avoid inbreeding depression and 500 to maintain evolutionary potential) is particularly relevant for MHC diversity, because the effective population size for MHC loci may be even lower than the genome-wide average due to balancing selection that was maintaining diversity before the bottleneck. Conservation strategies for genetically depauperate populations include maintaining the largest possible population sizes to minimize further drift, translocating individuals between subpopulations to introduce new MHC alleles, and banking gametes and tissues to preserve the remaining genetic diversity for future use.

Exercise 6

Exercise 6 (hard, analysis).

Explain how mRNA vaccines generate both humoral and cellular immunity, and why this dual activation is advantageous compared to traditional inactivated vaccines. What is the role of lipid nanoparticles in the immune response?

Hint

mRNA is translated into protein inside host cells. Endogenous protein is processed through the MHC class I pathway (CD8+ T cells). Secreted or exogenous protein is taken up by APCs and processed through the MHC class II pathway (CD4+ T cells and B cells).

Answer

mRNA vaccines generate dual immunity through the following mechanism. After intramuscular injection, lipid nanoparticles (LNPs) deliver nucleoside-modified mRNA into host cells (primarily muscle cells and dendritic cells at the injection site). The mRNA is translated by cellular ribosomes into the viral antigen (e.g., the SARS-CoV-2 spike protein).

Cellular immunity (CD8+ T cells): Because the antigen is synthesized inside the cell (endogenous synthesis), it enters the proteasomal degradation pathway. Peptide fragments are transported into the endoplasmic reticulum by TAP (transporter associated with antigen processing), loaded onto MHC class I molecules, and presented on the cell surface. CD8+ T cells that recognize these peptides become activated, proliferate, and differentiate into cytotoxic T lymphocytes capable of killing virus-infected cells.

Humoral immunity (B cells and antibodies): Some of the synthesized spike protein is secreted or displayed on the cell surface. This protein is taken up by professional antigen-presenting cells (dendritic cells), processed through the endosomal pathway, loaded onto MHC class II molecules, and presented to CD4+ helper T cells. Activated CD4+ T cells provide help to B cells that have bound the same antigen, leading to B cell proliferation, somatic hypermutation, and differentiation into antibody-secreting plasma cells and memory B cells.

Advantage over inactivated vaccines: Traditional inactivated vaccines deliver exogenous protein that is processed primarily through the MHC class II pathway, generating strong antibody responses but weak CD8+ T cell responses. The endogenous synthesis feature of mRNA vaccines generates robust CD8+ T cell immunity, providing an additional layer of protection (killing infected cells) that antibody-only responses cannot provide. This cellular immunity is particularly important against viruses that mutate surface proteins to escape antibody neutralization.

Role of LNPs: Lipid nanoparticles protect mRNA from enzymatic degradation, facilitate cellular uptake through endocytosis, and promote endosomal escape (releasing mRNA into the cytoplasm for translation). The ionizable lipid component of LNPs also has adjuvant properties: it stimulates innate immune receptors (including the inflammasome pathway), enhancing the adaptive immune response.

Exercise 7

Exercise 7 (medium, short answer).

Explain the concept of central tolerance in T cell development. How does AIRE (autoimmune regulator) contribute to preventing autoimmunity, and what happens when AIRE is mutated?

Hint

Central tolerance occurs in the thymus, where T cells that bind too strongly to self-peptides are deleted. AIRE allows thymic expression of tissue-specific antigens. What disease results from AIRE mutation?

Answer

Central tolerance is established during T cell development in the thymus through a two-step selection process:

Positive selection in the thymic cortex eliminates thymocytes whose T cell receptors (TCRs) cannot recognize self-MHC molecules at all (approximately 90% of thymocytes die by neglect). Only thymocytes that weakly bind self-MHC survive and receive a positive selection signal.

Negative selection in the thymic medulla eliminates thymocytes whose TCRs bind too strongly to self-peptide-MHC complexes. These strongly self-reactive thymocytes undergo apoptosis (clonal deletion), preventing them from entering the peripheral T cell pool and causing autoimmunity.

AIRE (autoimmune regulator) is a transcription factor expressed by medullary thymic epithelial cells (mTECs) that enables the thymus to present tissue-specific antigens -- proteins that are normally expressed only in specific peripheral organs (insulin from the pancreas, thyroglobulin from the thyroid, myelin basic protein from the nervous system). By expressing these antigens in the thymus, AIRE ensures that developing T cells are tested against a comprehensive panel of self-proteins before being released into the periphery. T cells that react strongly against any of these tissue-specific antigens are deleted.

APECED (autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy), also called APS-1, results from loss-of-function mutations in the AIRE gene. Without AIRE, tissue-specific antigens are not expressed in the thymus, and self-reactive T cells against pancreatic, thyroid, adrenal, and other tissue antigens escape deletion. The result is multiple autoimmune diseases: type 1 diabetes, hypothyroidism, hypoparathyroidism, adrenal insufficiency, and chronic mucocutaneous candidiasis, typically beginning in childhood. This demonstrates that AIRE-dependent central tolerance is essential for preventing systemic autoimmunity.

Exercise 8

Exercise 8 (medium, short answer).

Compare Type I hypersensitivity (allergy), Type II hypersensitivity (antibody-mediated), and Type IV hypersensitivity (delayed-type, T cell-mediated). For each, describe the mechanism and provide a specific clinical example.

Hint

Type I: IgE-mediated, immediate. Type II: IgG/IgM against cell-surface antigens. Type IV: T cell-mediated, delayed. Match each to examples like anaphylaxis, hemolytic anemia, and poison ivy.

Answer

Type I hypersensitivity (immediate, IgE-mediated): On first exposure to an allergen, CD4+ Th2 cells stimulate B cells to produce IgE antibodies, which bind to Fc receptors on mast cells and basophils. On re-exposure, the allergen cross-links IgE on mast cells, triggering degranulation and release of histamine, leukotrienes, and prostaglandins. This causes vasodilation, increased vascular permeability, bronchoconstriction, and mucus production. Examples: anaphylaxis to peanut protein (systemic, life-threatening), allergic rhinitis (hay fever, localized). Symptoms appear within minutes.

Type II hypersensitivity (antibody-mediated cytotoxicity): IgG or IgM antibodies bind to antigens on the surface of the body's own cells, marking them for destruction. Three mechanisms: (a) complement activation (MAC formation lyses the cell), (b) opsonization (macrophages phagocytose the antibody-coated cell), and (c) antibody-dependent cellular cytotoxicity (NK cells kill the antibody-coated cell). Examples: autoimmune hemolytic anemia (antibodies against red blood cells), Goodpasture syndrome (antibodies against basement membrane collagen in kidneys and lungs), hemolytic disease of the newborn (maternal antibodies against fetal Rh antigens).

Type IV hypersensitivity (delayed-type, T cell-mediated): Unlike Types I-III (which are antibody-mediated), Type IV is mediated by T cells and requires 24-72 hours to develop. Sensitized CD4+ Th1 cells (or CD8+ CTLs) encounter their specific antigen, release cytokines (IFN-gamma, TNF-alpha), and recruit macrophages and other inflammatory cells. The resulting inflammation damages tissue. Examples: contact dermatitis from poison ivy (urushiol binds to skin proteins, creating hapten-carrier complexes recognized by T cells), tuberculin skin test (injected Mycobacterium tuberculosis antigens trigger recall response in previously exposed individuals, producing induration at 48-72 hours), and graft rejection (T cells attack transplanted tissue expressing foreign MHC).

Connections Master

Cell signaling 17.07.01. Immune cell communication depends on the receptor signaling mechanisms described in 17.07.01. Cytokine receptors (IL-2 receptor, interferon receptors) activate JAK-STAT signaling, a direct application of the tyrosine kinase cascade principles. The T cell receptor complex associates with CD3 and zeta chain ITAMs (immunoreceptor tyrosine-based activation motifs), which recruit ZAP-70 kinase, initiating a signaling cascade analogous to RTK signaling. The NF-kappaB pathway, activated by TLRs, TNF receptor, and the T cell receptor, is one of the most important signaling cascades in immunology and connects directly to the cell signaling principles introduced in 17.07.01. B cell receptor signaling parallels TCR signaling, using the Syk kinase (analogous to ZAP-70) and downstream adapters including BLNK and PLC-gamma2.
Cell cycle 17.08.01. Clonal expansion of lymphocytes requires rapid cell division (a T cell can divide every 6-12 hours during peak expansion, producing thousands of daughter cells in days). This demands cell cycle control mechanisms that must balance proliferation with genome integrity. AID-mediated somatic hypermutation in B cells creates DNA damage that must be repaired accurately; failure of DNA repair during SHM can lead to chromosomal translocations (e.g., the BCL2-IgH translocation in follicular lymphoma, the MYC-IgH translocation in Burkitt lymphoma).
Molecular genetics 17.06.01. The generation of immune receptor diversity through V(D)J recombination is one of the few physiological processes that deliberately creates DNA double-strand breaks. The RAG1/RAG2 complex, which initiates V(D)J recombination, is evolutionarily derived from a transposase, suggesting that the adaptive immune system evolved when a transposable element inserted into a gene encoding a primitive innate immune receptor, creating the capacity for somatic DNA rearrangement. Somatic hypermutation by AID represents another deliberate mutagenesis process, creating mutations at a rate approximately one million times higher than the basal somatic mutation rate.
Body plans 18.01.01. The epithelial barrier (skin, mucous membranes) is both a body plan feature and the first line of innate immune defense. The tight junctions and stratified squamous keratinized epithelium of the skin provide physical protection against pathogen entry. The mucosal immune system (GALT, BALT, MALT) integrates barrier defense with adaptive immunity at body surfaces.
Reproductive biology 18.09.01. Maternal-fetal immune tolerance is a specialized application of the tolerance mechanisms described here. The placenta expresses non-classical MHC molecules (HLA-G) that engage inhibitory receptors on NK cells, and creates an immune-privileged site through local Treg enrichment, PD-L1 expression, and tryptophan depletion (by indoleamine 2,3-dioxygenase, IDO). The blood-testis barrier similarly creates an immune-privileged site for developing sperm. Recurrent pregnancy loss has been associated with abnormal uterine NK cell function and reduced Treg populations.
Conservation biology 19.14.01. Immunological competence affects population viability in conservation contexts. Reduced genetic diversity (MHC diversity in particular) in small, endangered populations increases susceptibility to epidemics. The cheetah's near-uniform MHC profile is thought to contribute to its vulnerability to infectious disease. Conservation genetics must consider immune gene diversity alongside neutral genetic markers when assessing population health. The Tasmanian devil's facial tumor disease, a transmissible cancer that spreads when devils bite each other during mating, exploits the devil's low MHC diversity: the tumor is not recognized as foreign because its MHC matches the host's, allowing unchecked growth.
Digestive physiology 18.06.01. The gut-associated lymphoid tissue (GALT) is the largest immune organ in the body, containing approximately 70% of the body's immune cells. Oral tolerance prevents immune responses to food antigens, and secretory IgA coats commensal bacteria. Disruption of gut immune homeostasis contributes to inflammatory bowel disease, celiac disease, and food allergies. The gut microbiome shapes immune development: germ-free mice have underdeveloped immune systems and are susceptible to infections that conventional mice resist.

Historical & philosophical context Master

Immunology began as the study of protection from infectious disease and became a general science of recognition, memory, tolerance, and defense. The field's history illustrates how biological disciplines are transformed by methodological innovations, and how practical concerns (preventing disease) can drive fundamental scientific discoveries.

Edward Jenner's smallpox vaccination in 1796, using cowpox (vaccinia virus) to protect against smallpox (variola virus), is often cited as the birth of immunology. Jenner observed that milkmaids who had contracted cowpox were immune to smallpox, and he tested the hypothesis by inoculating a boy with cowpox material and later challenging him with smallpox -- the boy was immune. This empirical observation preceded any understanding of the mechanism by a century. Pasteur's development of attenuated vaccines (anthrax, rabies) in the 1880s extended Jenner's approach, and his principle of isolating, attenuating, and inoculating pathogens established the conceptual framework for all subsequent vaccine development.

The cellular versus humoral debate of the late 19th century pitted Elie Metchnikoff (who discovered phagocytosis and championed cellular immunity) against Emil von Behring and Paul Ehrlich (who discovered antibodies and championed humoral immunity). The resolution, not achieved until the mid-20th century, was that both systems exist and cooperate: antibodies mark pathogens for phagocytosis (opsonization), T cells help B cells produce antibodies, and macrophages present antigens to T cells. This integration of cellular and humoral immunity is now a central principle of immunology, but the debate delayed the recognition of this synergy for decades.

The clonal selection theory, proposed by Macfarlane Burnet in 1957, provided the theoretical framework that unified cellular and humoral immunity. Burnet proposed that each lymphocyte expresses receptors specific for one antigen before encountering it, and that antigen binding selects the lymphocyte for clonal expansion. This theory explained specificity, memory, and tolerance (self-reactive clones are deleted during development). The theory was confirmed by the discovery that each B cell produces antibodies of a single specificity (Nossal and Lederberg, 1958) and by the elucidation of V(D)J recombination by Susumu Tonegawa (Nobel Prize 1987), which explained how the genetic diversity of antibodies is generated.

The discovery of MHC restriction by Zinkernagel and Doherty in 1974 revealed that T cells recognize antigen only in the context of self-MHC molecules, establishing the principle of self-non-self discrimination at the molecular level. This finding explained transplant rejection, MHC-associated disease susceptibility, and the evolutionary advantage of MHC polymorphism. The subsequent discovery of antigen processing pathways (proteasomal degradation for MHC class I, endosomal degradation for MHC class II) revealed the cellular logistics of peptide generation and presentation.

The philosophical dimensions of immunology center on the concept of self. The immune system must distinguish self from non-self, but the boundaries are more fluid than the simple dichotomy suggests. The gut microbiome is genetically non-self but functionally integrated. Pregnant women tolerate a fetus that is genetically semi-allogeneic. Cancer cells are genetically self but behave like non-self (evading growth controls). Autoimmune diseases represent a failure of self-tolerance. These complexities have led to proposals for alternative frameworks: Polly Matzinger's "danger model" proposes that the immune system responds not to non-self per se but to signals of tissue damage and stress; Pradeu and Carosella's "continuity theory" proposes that the immune system detects abrupt changes in the molecular patterns it encounters rather than static self-non-self distinctions. These frameworks are not mutually exclusive and are being integrated into a more nuanced understanding of immune recognition.

The modern discipline also faces ethical questions. Immunotherapy (checkpoint inhibitors, CAR-T cells) can produce dramatic cancer remissions but costs hundreds of thousands of dollars per treatment, raising questions about access and equity. Vaccine hesitancy, amplified by misinformation, threatens the herd immunity that protects immunocompromised individuals who cannot be vaccinated. The COVID-19 pandemic demonstrated both the power of immunological science (mRNA vaccines developed in under a year) and the fragility of public trust in that science.

The development of CAR-T cell therapy represents another frontier. Chimeric antigen receptor T cells are genetically engineered to express a synthetic receptor that combines an antibody-derived antigen-binding domain with T cell signaling domains, redirecting the patient's own T cells to recognize and kill tumor cells bearing a specific surface antigen. CD19-directed CAR-T cells have produced remarkable complete remission rates in patients with relapsed B cell acute lymphoblastic leukemia and diffuse large B cell lymphoma, including patients who had exhausted all other treatment options. However, CAR-T therapy can cause cytokine release syndrome (a systemic inflammatory response triggered by massive T cell activation) and neurotoxicity, requiring specialized management. The high cost (approximately $400,000 per treatment) and the requirement for personalized manufacturing limit access. These challenges exemplify the broader tension in modern immunology between therapeutic innovation and equitable access.

Bibliography Master

Campbell, N. A. & Reece, J. B. Biology, 12th ed. (Pearson, 2020). Ch. 43.
Abbas, A. K., Lichtman, A. H. & Pillai, S. Basic Immunology: Functions and Disorders of the Immune System, 6th ed. (Elsevier, 2022).
Murphy, K. & Weaver, C. Janeway's Immunobiology, 10th ed. (Garland Science, 2022).
Burnet, F. M. The Clonal Selection Theory of Acquired Immunity (Cambridge University Press, 1959).
Zinkernagel, R. M. & Doherty, P. C. "Restriction of in vitro T cell-mediated cytotoxicity in lymphocytic choriomeningitis within a syngeneic or semiallogeneic system." Nature 248 (1974) 701-702.
Tonegawa, S. "Somatic generation of antibody diversity." Nature 302 (1983) 575-581.
Matzinger, P. "The danger model: a renewed sense of self." Science 296 (2002) 301-305.
Sharma, P. & Allison, J. P. "The future of immune checkpoint therapy." Science 348 (2015) 56-61.
Pancer, Z. & Cooper, M. D. "The evolution of adaptive immunity." Annu. Rev. Immunol. 24 (2006) 497-518.
Hoffmann, J. A. "The immune response of Drosophila." Nature 426 (2003) 33-38.
Jenkins, M. K., Chu, H. H., McLachlan, J. B. & Moon, J. J. "On the composition of the preimmune repertoires of T and B cells." Immunity 33 (2010) 182-195.
June, C. H., O'Connor, R. S., Kawalekar, O. U., Ghassemi, S. & Milone, M. C. "CAR T cell immunotherapy for human cancer." Science 359 (2018) 1361-1365.

Prerequisites

17.03.01 pending
17.07.01 pending

Tier anchors

beginner: Campbell Biology, 12th ed. (2020), Ch. 43; Khan Academy Biology
intermediate: Abbas, Lichtman & Pillai — Basic Immunology, 6th ed. (2022)
master: Janeway's Immunobiology, 10th ed. (2022); Murphy & Weaver — Janeway; relevant primary literature

References

Campbell Biology, 12th ed. (Pearson, 2020) · Ch. 43 The Immune System
Abbas, A. K., Lichtman, A. H. & Pillai, S. — Basic Immunology: Functions and Disorders of the Immune System, 6th ed. (Elsevier, 2022) · Ch. 1-12
Murphy, K. & Weaver, C. — Janeway's Immunobiology, 10th ed. (Garland Science, 2022) · Ch. 1-16
Burnet, F. M. — The Clonal Selection Theory of Acquired Immunity (Cambridge University Press, 1959) · Theoretical framework for adaptive immunity
Zinkernagel & Doherty — Restriction of in vitro T cell-mediated cytotoxicity (Nature 1974) · MHC restriction discovery

Estimated time

beginner: 15m
intermediate: 35m
master: 55m